Ligand Pharmaceuticals LGND Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues and income by Product | ||||||
| Captisol | $35.41M-12.0% | $40.21M-0.3% | $40.34M+12.3% | $35.92M+2.2% | $35.13M+13.8% | |
| Capvaxive | $11.14M+10.8% | $10.06M+54.0% | $6.53M+73.7% | $3.76M— | —— | |
| Contract revenue | $62.6M-6.4% | $66.87M+689% | $8.47M-61.8% | $22.19M— | —— | |
| Filspari | $37.99M+18.8% | $31.97M+24.2% | $25.73M+29.6% | $19.86M+26.4% | $15.71M+29.0% | |
| Qarziba | $24.6M+3.6% | $23.74M-0.2% | $23.8M+6.0% | $22.45M+35.5% | $16.56M+48.9% | |
| Vaxneuvance | $7.73M+4.4% | $7.4M+3.0% | $7.19M+8.7% | $6.62M+30.2% | $5.08M-2.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ligand Pharmaceuticals break its business down?
- Ligand Pharmaceuticals (LGND) reports total revenues and income by product across 12 parts — Captisol, Capvaxive, Contract revenue, Filspari and Kyprolis. Each is extracted from the segment footnotes and tracked over time.
- Where does Ligand Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ligand Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.